Pathology
 |
|
13 february 2020 13:01:03 |
| Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer (Prostate Cancer and Prostatic Diseases) |
|
Tweet |
| 187 viewsCategory: Oncology, Pathology |
 Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI (Prostate Cancer and Prostatic Diseases)Copy number alterations are associated with metastatic-lethal progression in prostate cancer (Prostate Cancer and Prostatic Diseases) 
|
| blog comments powered by Disqus |
MyJournals.org
The latest issues of all your favorite science journals on one page
The latest issues of all your favorite science journals on one page
